Interleukin 2 gene therapy of surgical minimal residual tumour disease: Characterization of cytolytic effector cells from tumour progressors and regressors

Folia Biologica

Volumn 45, Issue 6, 1999, Pages 227-231

  Hajkova R ^a   Indrova M ^a   Jandlova T ^a   Bubenik J ^a   Reinis M ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Gene therapy; Interleukin 2; Residual tumour disease

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE THERAPY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; RECURRENCE RISK; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; TUMOR RECURRENCE;

ANIMALIA; MURINAE;

EID: 0032700276     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ballas, Z. K., Rasmussen, W. (1990) Lymphokine-activated killer (LAK) cells: IV. Characterisation of murine LAK effector subpopulations. J. Immunol. 144, 386-95.
2. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shah, K. V. (1995) Prevalence of human papillomavirus in cervical cancer, a worldwide perspective. J. Natl. Cancer Inst. 87, 796-802.
3. Bubeník, J., Indrová, M., Němečková, S., Malkovský, M., von Broen, B., Pálek, V., Anderlíková, J. (1978) Solubilized tumor-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation test. Int. J. Cancer 21, 348-335.
4. Bubeník, J., Ǐndrová. M., Perlmann, P., Berzins, K., Mach, O., Kraml, J., Toulcová, A. (1985) Tumour inhibitory effects of TCGF/IL-2/-containing preparations. Cancer Immunol. Immunother. 19, 57-61.
5. Bubeník, J., Zeuthen, J., Indrová, M., Bubeníková, D., Šímová, J. (1994) Kinetics and functions of peritoneal exudate cells during local IL-2 gene therapy of cancer. Int. J. Oncol. 4, 13-16
6. Bubeník, J., Šímová J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 596-597.
7. Gillis, S., Ferm, M. M., Ou, W., Smith, K. A. (1978) T-cell growth factor parameters of production and a quantitative microassay for activity. J. Immunol. 120, 2027-2032.
8. Goldie, H., Butler, C. H., Anderson, M. M. (1953) Growth characteristics of free C1498 (granulocytic leukaemia) tumour cells in the peritoneal fluid and the blood of C57 mice. Cancer Res. 13, 125-129.
9. Kalland, T., Belfrage, H., Bhiladvala, P., Hedlund, G. (1987) Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effector cells and progenitors into NK- and T-like cells. J. Immunol. 138, 3640-3645.
10. Quintin-Colona, F., Devauchelle, P., Fradelizi, D., Mourot, B., Faure, T., Kourilsky, P., Roth, C., Mehtali, M. (1996) Gene therapy of spontaneous canine melanoma and feline fibro-sarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 3, 1104-1112.
11. Rössner, P., Bubeník, J., Indrová, M., Sobota, V., Vondrys, P., Zeuthen, J., Jandlová, T., Takáč, M. (1997) Genetically modified tumour vaccines: insertion of the IL-2 gene down-regulates tumorigenicity more efficiently than insertion of the CD80 gene. Int. J. Oncol. 10, 77-82.
12. Sobota, V., Bubeník, J., Indrová, M., Vlk, V., Jakoubková, J. (1997) Use of cryopreserved lymphocytes for assesment of the immunological effects of interferon therapy in renal cell carcinoma patients. J. Immunol. Methods 203, 1-10.
13. Thomas, M. C., Greten, T. F., Pardoll, D. M., Jaffee, E. M. (1998) Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Human Gene Ther. 9, 835-843.
14. Vlk, V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.
15. Wigzell, H., Ramstedt, U. (1986) Natural killer cells. In: Cellular Immunology, Vol. 2, ed. Weir, M. M., pp. 601-609, Blackwell Scientific Publ., Oxford.
16. Zur Hausen, H. (1996) Papillomavirus infections -major cause of human cancers. Biochim. Biophys. Acta 1288, F55-F58.